Results: Initial enterochromaffin cell counts were increased and correlated with initial lamina propria T-lymphocyte counts (r ¼ 0.460, P ¼ 0.014). Enterochromaffin cell counts did not change significantly after either prednisolone () 0.8% ± 9.2%) or placebo (7.9% ± 7.9%) (P ¼ 0.5). Although lamina propria T-lymphocyte counts decreased significantly after prednisolone (22.0% ± 5.6%, P ¼ 0.003), but not after placebo (11.5% ± 8.6%, P ¼ 0.1), this was not associated with any significant treatment-related improvement in abdominal pain, diarrhoea, frequency or urgency. Conclusions: Prednisolone does not appear to reduce the number of enterochromaffin cells or cause an improvement in symptoms in post-infectious irritable bowel syndrome. Other approaches to this persistent condition are indicated.
INTRODUCTION
Post-infectious irritable bowel syndrome, the onset of new irritable bowel syndrome symptoms after gastroenteritis, is well documented, 1, 2 and, depending on the setting, occurs in 4-32% of individuals after infection. [3] [4] [5] [6] [7] Post-infectious irritable bowel syndrome (PI-IBS) has a number of distinctive features, including lower levels of anxiety, 1 diarrhoea predominance 3, 8 and increased numbers of immunocytes in rectal biopsies, 9 which suggest a different pathogenesis from other forms of irritable bowel syndrome. Quantitative studies of the rectal mucosa have demonstrated increased numbers of chronic inflammatory cells 4 and entero-endocrine cells 10 in post-infectious irritable bowel syndrome. Furthermore, enterochromaffin cell and lymphocyte numbers are closely correlated, 10 suggesting a possible causal link.
Enterochromaffin cells, which contain 85% of the body's total serotonin stores, play a key role in transducing luminal stimuli, such as nutrients and pressure. These stimuli release serotonin, which acts on visceral afferents, both extrinsic and intrinsic, mediating both pain perception and the peristaltic reflex, in addition to regulating intestinal secretions. 11 5-Hydroxytryptamine-3 (5HT 3 ) antagonists improve the symptoms of diarrhoea-predominant irritable bowel syndrome, 12 leading to the hypothesis that a reduction in the number of enterochromaffin cells may benefit patients with post-infectious irritable bowel syndrome, whose symptoms are similar to those of diarrhoea-predominant irritable bowel syndrome. Animal models of post-infectious irritable bowel syndrome suggest that T lymphocytes play an important role in mediating the long-term effects of infection on neuromuscular function, 13 and that steroids can prevent the long-term dysfunction seen after Trichinella spiralis infection. 14 The aim of this study was to assess whether a short course of oral corticosteroids could reduce inflammation and enterochromaffin cell numbers, and thereby improve symptoms, in post-infectious irritable bowel syndrome.
METHODS

Patients
Originally, we planned to recruit all patients from the community who had developed new irritable bowel syndrome symptoms following a positive Campylobacter jejuni or C. coli stool culture. Between September 1999 and September 2001, questionnaires detailing the acute symptoms of gastroenteritis, and current and previous bowel habits, were sent to all subjects aged 18-75 years, 3 months after a positive stool culture for Campylobacter within the Nottingham Health Authority area. Those who responded and recorded new irritable bowel syndrome symptoms in accordance with the modified Rome I criteria 15 were invited to take part. However, the number of patients with postinfectious irritable bowel syndrome who could be contacted and agreed to take part in the study was very low. We therefore extended the inclusion criteria to include patients who had a clear history of new irritable bowel syndrome symptoms following an acute infection and who had been referred to gastroenterology outpatients, often with a previously positive stool culture. We defined post-infectious irritable bowel syndrome as new bowel symptoms developing in a previously asymptomatic individual immediately after an acute illness characterized by two or more of the following: diarrhoea, vomiting, fever or positive stool culture. The study was approved by the University Hospital Nottingham Ethics Committees. All patients gave written informed consent.
Trial protocol
The study was a randomized, double-blind, placebocontrolled trial of prednisolone, 30 mg once daily, for 3 weeks. Prednisolone 30 mg or placebo was supplied within a single gelatine capsule. A designated pharmacist generated random sequences in blocks of six, five times. The medication was allocated in numbered containers, which were dispensed by the pharmacist after patient enrolment by a clinician (S.P.D.). Patients were initially assessed at the hospital and then 6 weeks later. There was a 2-week run-in period, followed by 3 weeks of taking the medication at breakfast time. There was a further week without medication prior to the second assessment. A symptom diary was maintained over the full 6 weeks. As this was a mechanistic study, the analysis was per protocol rather than intention-to-treat, with dropouts replaced. The inclusion criteria were as follows: age, 18-65 years; the presence of Rome I criteria irritable bowel syndrome symptoms 15 immediately following a well-defined infective episode; and the presence of these symptoms for more than 3 months. Exclusion criteria were as follows: abnormal screening investigations; previous diagnosis of irritable bowel syndrome prior to gastroenteritis; known chronic gastrointestinal disorder; use of systemic steroids within the previous 4 months; clinically significant hepatic, renal or cardiac dysfunction; diabetes mellitus; active infection; active peptic ulcer; immunosuppression; alcoholism; gout; previous venous or arterial thrombus; known thrombophilic disorder; current or previous depression requiring ongoing drug therapy; or pregnancy.
Clinical and laboratory assessments
At the screening visit and 6 weeks later, patients filled in questionnaires and underwent a general examination, including rigid sigmoidoscopy and rectal biopsy. Blood was taken for full blood count, haematinics, thyroid function, liver function, calcium, C-reactive protein and anti-endomysial antibody at the screening visit. A repeat stool culture was also sent to exclude recurrent or persistent infection. On both visits, patients completed the following questionnaires: gastrointestinal symptom rating scale, 16 irritable bowel syndrome quality of life questionnaire, 17 modified
Talley bowel symptom questionnaire, 18 hospital anxiety and depression scale 19 and global score of wellbeing. The gastrointestinal symptom rating scale uses a Likert scale to produce separate summed scores for abdominal pain syndrome, reflux syndrome, indigestion syndrome and constipation syndrome. The irritable bowel syndrome quality of life questionnaire also uses a summed score for bowel symptoms, fatigue, limitations of activity and emotional function. Anxiety and depression scores indicate normal (0-7), mild (8-10), moderate (11) (12) (13) (14) or severe (14-21) levels. The global score of well-being is marked on a linear scale, from the worst (0) to the best (100) health that the patient has ever known.
Patients recorded in a diary the severity of abdominal pain or discomfort (0, none; 1, mild; 2, moderate; 3, intense; 4, severe), stool consistency (1, very hard; 2, hard; 3, formed; 4, loose; 5, watery), urgency (present or absent) and the number of stools per day. At the end of each week, there was a yes or no response to adequate relief of irritable bowel syndrome pain or discomfort and adequate relief of diarrhoea within the last 7 days. Adverse events were recorded and the questionnaires and rectal biopsy were repeated at week 6. A further modified Talley questionnaire was sent to patients at 3 months with a yes or no response to whether their bowel symptoms were still troublesome. A final questionnaire was sent 1 year later, asking whether abdominal symptoms were still troublesome. All data were analysed prior to the treatment code being broken.
Rectal biopsy
Rigid sigmoidoscopy was performed without bowel preparation. At each visit, two rectal biopsies were obtained using endoscopic biopsy forceps (FB-13K-1, Olympus, Japan), and these were gently flattened on filter paper, fixed in formalin and embedded in paraffin wax with orientation optimized using a dissecting microscope to ensure that sections were perpendicular to the mucosa. A single expert pathologist (D.J.) performed conventional histological assessment on haematoxylin-eosin sections using standardized published criteria. 20 All sections appeared normal using these criteria.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (4 lm) were mounted on pre-coated slides (Dako, Glostrup, Denmark . Lamina propria and intra-epithelial T lymphocytes were stained with primary rabbit polyclonal antibodies to CD3 (diluted 1 : 100, Dako). All sections were stained with a secondary biotinylated goat anti-mouse and anti-rabbit antibody as part of the automated process.
Methods of cell counting
Sections were oriented so that the full mucosal height was visible. Enterochromaffin cells, lamina propria lymphocytes and mast cells were counted within four non-overlapping, high-power fields (·200 magnification) on a single microscope by one person (S.P.D.). Sections were assessed with the operator blind to the clinical details. Entero-endocrine cells were counted if there was a visible nucleus surrounded by dark-stained granules. CD3-positive lymphocytes and mast cells were easily recognizable. Fields containing parts of lymphoid aggregates were avoided. All mast cells that were quantified were within the lamina propria. The mean numbers of entero-endocrine cells, mast cells and lamina propria T lymphocytes were expressed per high-power field. Using four fields for cell counting at ·200 magnification gave coefficients of variability of 7.2%, 6.8% and 6.9% for entero-endocrine cells, lamina propria T lymphocytes and mast cells, respectively (n ¼ 10 biopsies). Intra-epithelial lymphocytes were counted per 500 epithelial cells as described previously. 21 Surface intra-epithelial lymphocytes were counted between crypts and crypt intra-epithelial lymphocytes were counted within longitudinal crypts spanning the full mucosal thickness.
Outcome measures
The objective of the study was to investigate whether prednisolone reduced the number of serotonincontaining enterochromaffin cells. The primary outcome measure was therefore a reduction in the number of enterochromaffin cells per high-power view. Secondary outcome measures included a reduction in the number of lamina propria T lymphocytes, a reduction in the modified gastrointestinal symptom rating scale score and the presence of troublesome symptoms at 3 months. A modified gastrointestinal symptom rating scale was used employing the four variables of abdominal pain, looseness, urgency and frequency, because diarrhoea predominance is common in post-infectious irritable bowel syndrome. 8 Each variable was scored in the range 1-7 (no symptoms at all to very severe symptoms), 22 so that a maximum score of 28 was possible.
Power calculation
We estimated from our previous study 10 that a total of 30 patients would give 90% power to show a reduction of 33% in enterochromaffin cell counts at the 5% significance level.
Statistical analysis
Data were analysed per protocol. Parametric data are shown as the mean (standard error of the mean), whereas non-parametric data are reported as the median (interquartile range). Comparisons between parametric data were made using paired t-tests for individual responses and unpaired t-tests for initial values of the groups using SPSS for Windows Version 9 (SPSS Inc., Chicago, IL, USA). Correlations were assessed using the Pearson correlation coefficient.
RESULTS
Over the 2-year period, questionnaires were sent to 1407 patients with positive stool culture for Campylobacter. There were 635 replies, 75 of which were excluded (incomplete, n ¼ 29; pre-existant irritable bowel syndrome, n ¼ 37; other significant disease, n ¼ 9), leaving 560 questionnaires suitable for evaluation ( Figure 1 ). Of these, 66 patients had new symptoms of irritable bowel syndrome following infection (12% incidence). A further 47 patients (8%) developed two or more significant bowel symptoms. Fifty-one patients were invited to take part in the study. Twenty of the 36 patients with post-infectious irritable bowel syndrome from the community study were randomized and 17 completed the study. Fourteen of the 15 patients with post-infectious irritable bowel syndrome from the clinic were randomized and 12 completed the study (Figure 1) . Of the 29 patients who completed the study, 22 had diarrhoea-predominant irritable bowel syndrome, two had constipationpredominant irritable bowel syndrome and five had alternating symptoms. There were no differences in symptoms between those recruited from the community or the clinic, or between those randomized to receive prednisolone or placebo (Tables 1 and 2 ). Overall, the mean number of days per week with abdominal pain or discomfort was 2.4 ± 0.4 (graded between mild and moderate in severity) and the mean bowel frequency was 2.6 ± 0.3 per day. The relative frequencies of symptoms occurring more than 25% of the time were as follows: loose motions or diarrhoea, 86%; urgency, 79%; sense of incomplete evacuation, 79%; bloating, 69%; more than three stools per day, 41%; straining, 34%; hard motions, 32%; passing mucus, 24%; less than three stools per week, 10%.
Overall, the treatment was well tolerated. No sideeffects were reported by seven of 14 patients (50%) taking prednisolone and 10 of 15 patients (67%) taking placebo. The reported side-effects in the prednisolone group were heartburn (n ¼ 3), mood disturbance (n ¼ 4), acne (n ¼ 2) and single reports of insomnia, weight gain, palpitations, bruising, arthralgia, increased appetite and moon facies. In the placebo group, patients reported heartburn (n ¼ 3), mood disturbance (n ¼ 2) and single reports of insomnia, weight gain and headache. Five patients were screened and randomized but did not complete the study. Three patients were given the medication but did not take any of it for fear of possible steroid side-effects. Two patients, randomized to receive prednisolone, failed to complete the treatment course. One was withdrawn due to severe heartburn and acid regurgitation symptoms after 1 week, and the other declined to continue after noticing moderate ankle swelling after 3 days. Both patients were replaced without the randomization code being broken.
Rectal histology
The number of enterochromaffin cells was elevated (mean, 37.3 ± 1.3 per high-power field; range, and was correlated with the number of lamina propria T lymphocytes (r ¼ 0.460, P ¼ 0.014), confirming previous results. However, there was no significant reduction in the number of enterochromaffin cells after prednisolone compared with placebo (Table 3) . Although there was a significant reduction in the number of lamina propria T lymphocytes after prednisolone (22.0% ± 5.6%, P ¼ 0.003), but not after placebo (11.5% ± 8.6%, P ¼ 0.1), these differences were not statistically significant. There were no significant reductions in mast cells, crypt intra-epithelial lymphocytes or surface intra-epithelial lymphocytes in either treatment group (Table 3) .
Symptoms
Neither prednisolone nor placebo treatment was associated with any significant reduction in the daily scores of abdominal pain, consistency, urgency or stool frequency throughout the 6-week study period. Although there was a decrease in the modified gastrointestinal symptom rating scale score in the placebo group (P < 0.02), this decrease was not statistically different from that observed in the prednisolone group (P ¼ 0.1) ( and the gastrointestinal symptom rating scale, there were no significant differences in score reductions for any of the syndromes of bowel symptoms, fatigue, activity limitation or emotional function, apart from constipation. The constipation syndrome score was reduced more in the placebo group (1.0 ± 0.33) than in the prednisolone group () 0.4 ± 0.55) (P ¼ 0.035). Scores for anxiety, depression and global well-being showed no significant change in either treatment group. The questionnaire at 3 months was returned by 21 of the 29 patients. Of the 19 who answered the question, 'Are your symptoms still troublesome?', three of nine in the prednisolone group and four of 10 in the placebo group replied 'yes' (P ¼ 0.8). Patients were asked at 1 year if, over the last 12 months, troublesome bowel symptoms were still present. Replies were received from 20 of the 29 patients. Bowel symptoms remained in eight of 11 given steroids and seven of nine given placebo (P ¼ 0.8).
DISCUSSION
There is a growing body of evidence indicating that lowgrade inflammation may underlie some cases of diarrhoea-predominant irritable bowel syndrome, 23, 24 particularly those developing after infection. 10 Our study is therefore of particular importance, as it is the first report of an attempt to modify the disease process in irritable bowel syndrome rather than to simply suppress symptoms. This attempt is justified by our recent study, which showed that post-infectious irritable bowel syndrome is not a transient condition, with more than one-half of patients remaining symptomatic 6 years after infection. 8 Our earlier studies suggested that increased serotonin-containing entero-endocrine cells were a frequent finding in such patients, 9 and that enterochromaffin cell numbers correlated with lymphocyte counts, 10 suggesting a possible causal link. This trial aimed to test whether suppression of the lymphocyte count with prednisolone would reduce enterochromaffin cell numbers and possibly improve symptoms. During the study, we encountered a number of obstacles which need to be taken into account when assessing the significance of our negative result. Firstly, it proved to be extremely difficult to recruit patients with post-infectious irritable bowel syndrome, as they felt that their symptoms did not warrant the perceived risk of steroid therapy. This is a common feature in irritable bowel syndrome, indicating that even an effective medication would not be acceptable unless it had a better safety profile than prednisolone, even at doses similar to those in frequent use in the community for asthma. Despite this perception, prednisolone was in fact well tolerated overall, with only one patient being withdrawn because of a significant adverse reaction: severe gastro-oesophageal reflux. Therefore, we had to extend our study criteria to include those referred to gastroenterology out-patients, who proved to be slightly easier to recruit. However, there were no differences in terms of rectal histology, severity of symptoms or anxiety or depression scores between these groups, suggesting that our results can be generalized to patients with post- infectious irritable bowel syndrome in both primary and secondary settings. Secondly, our previous experience indicated that the need for rectoscopy and biopsy was a major deterrent to recruitment, and so this was kept to a minimum. However, this meant that we could only obtain histology at one time point. Our decision to biopsy at 4 weeks after the start of prednisolone was a compromise between the desire to avoid too long an interval, with the risk of other intervening factors diluting the drug effect, and too short an interval, which might miss a more slowly developing response. We cannot exclude the possibility that we may not have allowed enough time for enterochromaffin cell numbers to change. Animal studies have suggested that there are two populations of enterochromaffin cells: most have a half-life around four times that of surrounding enterocytes, whereas a smaller longer lived population have a half-life around 30 times that of surrounding enterocytes. 25 Extrapolation from this would indicate that most human enterochromaffin cells have half-lives of 1-2 weeks, although this has not been measured directly. If this were true, then changes should have been apparent at 4 weeks. Mucosal lymphocyte counts decreased with prednisolone, but the effect was small in comparison with placebo, probably because the baseline continued to fall. Larger numbers of patients would have helped here, but the difficulty in recruitment precluded this. One explanation for our findings is that the previously noted correlation between lymphocyte and enterochromaffin cell numbers is not due to the stimulation of the production of enterochromaffin cells from stem cells by lymphocyte-derived factors, but rather because an enterochromaffin cell product, namely serotonin, encourages the migration of circulating lymphocytes into the mucosa. This pro-inflammatory effect of serotonin is thought to be due to the stimulation of 5HT 2 receptors on vascular smooth muscle cells causing increased permeability. 26 Previous studies using the same animal model have indicated that, although postinfective neuromuscular dysfunction appears to be lymphocyte dependent in the first few days, later, cyclo-oxygenase-2 induction may be more important, 27 but this has never been assessed in humans. Finally, we should consider the possibility that increased mucosal lymphocytes and enterochromaffin cells do not cause symptoms, but are merely markers of previous inflammation, which causes symptoms by other mechanisms, such as damage to mucosal nerves, as reported by several authors. [28] [29] [30] The inflammatory response to Campylobacter infection is most obvious in the terminal ileum and on the right side of the colon. We used enterochromaffin cells in rectal biopsies as markers of inflammatory damage elsewhere, as we did not feel that we could justify repeated colonoscopy. We are currently attempting to develop non-invasive measures of disturbed function in post-infectious irritable bowel syndrome which assess other involved areas, including gut permeability and the release of serotonin after a meal. These may be more strongly associated with symptom severity and may provide better ways of assessing new treatments in the future. At present, in spite of the small size of our study, we can be confident that, for reasons of patient acceptability and efficacy, prednisolone is not likely to be an effective treatment for post-infectious irritable bowel syndrome. Whether a more prolonged course of topically active steroid or a cyclo-oxygenase-2 inhibitor would be more effective remains to be determined.
